Clinical Competition Candidate
RYTARY
RYTARY carries product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 30 months away. Active clinical competition may compress the generic entry window.
LOE window
30months
to latest listed patent expiry (December 26, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 15
Complexity score: 3/5
Clinical competition
Score: 5/5
Active trials linked: 313
Phase 2/3 trials: 156
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: CARBIDOPA; LEVODOPA
Applicant (NDA holder): IMPAX LABORATORIES LLC
Confidence: High